

Supplementary Table 6. Demographics and clinicopathologic characteristics of patients among groups N0, A + B, and C

Characteristic	Group N0	Group A + B	Group C	P-value
Age (yr)				0.532
≤60	35 (62.5)	20 (52.6)	25 (64.1)	
>60	21 (37.5)	18 (47.4)	14 (35.9)	
Sex				0.927
Male	29 (51.8)	18 (47.4)	20 (51.3)	
Female	27 (48.2)	20 (52.6)	19 (48.7)	
Hemoglobin (g/L)				0.166
≤130	29 (51.8)	19 (50.0)	27 (69.2)	
>130	27 (48.2)	19 (50.0)	12 (30.8)	
Serum albumin (g/L)				0.187
≤35	5 (8.9)	2 (5.3)	7 (18.0)	
>35	51 (91.1)	36 (94.7)	32 (82.1)	
TBIL (μmol/L)				0.222
≤17.1	37 (66.1)	27 (71.1)	32 (82.1)	
>17.1	19 (33.9)	11 (29.0)	7 (18.0)	
ALT (U/L)				0.475
≤40	33 (58.9)	27 (71.1)	26 (66.7)	
>40	23 (41.1)	11 (29.0)	13 (33.3)	
γ-GT (U/L)				0.257
≤50	13 (23.2)	4 (10.5)	9 (23.1)	
>50	43 (76.8)	34 (89.5)	30 (76.9)	
PT (sec)				0.690
≤14	55 (98.2)	36 (94.7)	38 (97.4)	
>14	1 (1.8)	2 (5.3)	1 (2.6)	
INR				0.426
≤1.15	54 (96.4)	35 (92.1)	35 (89.7)	
>1.15	2 (3.6)	3 (7.9)	4 (10.3)	
HBsAg				0.902
Negative	41 (73.2)	30 (78.9)	29 (74.4)	
Positive	14 (25.0)	8 (21.1)	10 (25.6)	
Missing	1 (1.8)	0 (0)	0 (0)	
CEA (μg/L)				0.119
≤5	39 (69.6)	20 (52.6)	20 (51.3)	
>5	17 (30.4)	18 (47.4)	19 (48.7)	
CA 125 (U/mL)				0.057
≤35	43 (76.8)	22 (57.9)	22 (56.4)	
>35	13 (23.2)	16 (42.1)	17 (43.6)	
CA 19-9 (U/mL)				0.411
≤35	19 (33.9)	8 (21.1)	11 (28.2)	
>35	37 (66.1)	30 (79.0)	28 (71.8)	
Tumor number				0.620
1	44 (78.6)	24 (63.2)	29 (74.4)	
>1	9 (16.1)	10 (26.3)	9 (23.1)	
Missing	3 (5.3)	4 (10.5)	1 (2.5)	
Tumor size (cm)				0.062
≤5	25 (44.6)	17 (44.7)	10 (25.6)	
>5	27 (48.2)	18 (47.4)	28 (71.8)	
Missing	4 (7.2)	3 (7.9)	1 (2.6)	
Tumor type				0.573
Non-mass-forming	7 (12.5)	2 (5.3)	4 (10.3)	
Mass-forming	49 (87.5)	36 (94.7)	35 (89.7)	
Surgical margin				0.773
R0	52 (92.9)	36 (94.7)	35 (89.7)	
R1	4 (7.1)	2 (5.3)	4 (10.3)	
No. of LNs harvested				0.006
<6	37 (66.1)	13 (34.2)	17 (43.6)	
≥6	19 (33.9)	25 (65.8)	22 (56.4)	

Supplementary Table 6. Continued

Characteristic	Group N0	Group A + B	Group C	P-value
Vascular invasion				0.067
No	43 (76.8)	28 (73.7)	23 (59.0)	
Yes	10 (17.9)	8 (21.1)	14 (35.9)	
Missing	3 (5.3)	2 (5.2)	2 (5.1)	
Surgery time (min)				0.593
≤300	32 (57.1)	21 (55.3)	16 (41.0)	
>300	24 (42.9)	17 (44.7)	23 (58.97)	
Blood loss (mL)				0.282
≤300	32 (57.1)	21 (55.3)	16 (41.0)	
>300	24 (42.9)	17 (44.7)	23 (59.0)	
Blood transfusion				0.813
No	39 (69.6)	28 (73.7)	26 (66.7)	
Yes	17 (30.4)	10 (26.3)	13 (33.3)	
Postoperative hospital stay (day)				0.974
≤12	35 (62.5)	23 (60.5)	23 (59.0)	
>12	21 (37.5)	15 (39.47)	16 (41.0)	
Postoperative complication				0.622
No	43 (76.8)	31 (81.6)	33 (84.6)	
Yes	13 (23.2)	7 (18.4)	6 (15.4)	
Adjuvant treatment				0.321
No	53 (94.6)	33 (86.8)	37 (94.9)	
Yes	3 (5.4)	5 (13.2)	2 (5.1)	

Values are presented as number (%).

TBIL, total bilirubin; INR, international normalized ratio; LN, lymph node.